Genprex

Category: Press Releases

Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers

Expands on the previously granted patents covering the use of REQORSA in combination with immune checkpoint inhibitors applicable to Genprex’s Acclaim-2 and Acclaim-3 clinical trials

Read More


Genprex Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators 

Three Collaborators Selected to Present Positive Nonclinical Data on Genprex Oncology Program at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Read More

Genprex to Present at Upcoming BIO CEO & Investor Conference

Presentation to Highlight Company’s Gene Therapies for Cancer and Diabetes

Read More


Genprex Announces 1-for-40 Reverse Stock Split Effective February 2, 2024

Genprex today announced that on February 2, 2024, the Company will implement a 1-for-40 reverse split of its issued and outstanding common stock, par value $0.001 per share.

Read More

Genprex Provides Business Update and Outlook for 2024 

Acclaim-1 Phase 2a and Acclaim-3 Phase 1 clinical studies opening for enrollment in January 2024

Poised for FDA guidance regarding diabetes gene therapy program in 2024

Read More

Genprex to Present at BIO-Europe 2023 Conference 

Presentation to be held on Tuesday, November 7, 2023 from 4:45 – 5:00 p.m. UTC

Read More

Genprex to Host a Virtual Key Opinion Leader Event on “Bringing Gene Therapy  to the Fight Against Lung Cancers”

Webinar to be held on Friday, October 27, 2023 from 12:30 pm – 1:45 pm Eastern Time

Read More

Genprex to Present Data on the Use of REQORSA® for the Treatment of Lung Cancers at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Acclaim-1 Phase 1 study had no Dose Limiting Toxicity, and results establish Phase 2 Recommended Dose as well as provide data showing efficacy of REQORSA® in combination with Tagrisso®

Read More